Alzinova AB ALZ

OMXSTO · Sweden · Health Technology

SEK 0.4070-0.01 (-2.86%)

Market closed· Oct 1, 2026, 3:29 PM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Alzinova AB ALZ

OMXSTO · Sweden · Health Technology

SEK 0.4070-0.01 (-2.86%)

Market closed· Oct 1, 2026, 3:29 PM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-32.62% · 6MFull-screen chart

Open SEK 0.4255High SEK 0.4255Low SEK 0.3910Close SEK 0.4070Volume 2.50M

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: SEK 0.4190
Day range: SEK 0.3910 – SEK 0.4260
52-week range: SEK 0.3820 – SEK 2.28
Volume: 2.50M
Market cap: SEK 135.85M
Next earnings date: 2026-11-12
Avg. volume (1Y): 2.19M

Performance

1 week

-1.81%

1 month

-49.63%

3 months

-17.78%

6 months

-31.60%

Year to date

-51.55%

1 year

-63.73%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Sweden
Exchange: OMXSTO
Shares outstanding: 324.23M
ISIN: SE0007413455
Beta: 0.84

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 21, 2026

Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need

ALZ-101 ALZ-101, Alzinova’s therapeutic vaccine candidate for Alzheimer’s disease. GOTHENBURG, Sweden, Sept. 21, 2026 (GLOBE NEWSWIRE) -- As World Alzheimer’s Day highlights the continued unmet need in Alzheimer’s disease, Swedish clinical-stage biopharmaceutical company Alzinova AB (Nasdaq First North: ALZ) is advancing on two fronts: initiating the global Phase II start-up of its therapeutic vaccine ALZ-101 while advancing a blood-based diagnostic program based on the same proprietary technolo

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.